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ABSTRACT 
Hepatitis B virus (HBV) infection is associated with chronic liver diseases, cirrhosis and hepatocellular carcinoma, liver 
failure and death. The prevalence of Hepatitis B virus carrier and infectivity status and social characteristics among three 
hundred and ten pregnant women in Logo LGA, Benue State, Nigeria, was determined through random anonymous testing 
of volunteers attending antenatal clinics of different hospitals within the community. Thirty of three hundred and ten 
blood samples tested positive for HBV infection. 11.9% were in the 3rd trimester of their pregnancy and 58.1% were within 
the age bracket of 21-30 years. Illiterates women constituted 14.4% of those sampled while civil servants were 6.7%. HBV 
carrier status was determined by the presence of Hepatitis B surface antigen (HBsAg). Repeated reactive samples were 
confirmed by Enzyme linked immounosorbent assay (ELISA) Kit (Diagnostic Automation, Inc., USA). Maternal HBV 
infectivity status was determined by testing all HBsAg positive samples for the presence of hepatitis B e antigen (HBeAg). 
A total of thirty (9.7%) pregnant women identified as carriers of HBV and eleven of the thirty tested positive for HBeAg. 
Hence, 3.6% (11/310) of the entire study population was found to have high viral replication as well as high risk of 
transmitting HBV to their neonates. The frequency of HBV carrier did not vary with age, however, it varies significantly 
with the previous use of contraceptives and the anaemic status of the subjects (P< 0.05) .This study demonstrates the 
endemicity of HBV infection in Logo and high infectivity rate, suggest that HBV is likely to be acquired by both vertical 
and horizontal means of transmission. Testing for HBsAg is recommended for all pregnant women at first prenatal visit so 
that positive mothers receive prompt intervention. 
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RÉSUMÉ  
L’infection de virus de l’hépatite B (VHB) est associée aune malade chronique du foie, la cirrhose et carcinome 
hépatocellulaire, insuffisance hépatique et la mort. La prévalence du porteur de virus de l’hépatite B et le statut de 
l’infectiosité et de caractéristiques sociales chez trois cent dix femmes enceintes a la zone de gouvernement local de Logo 
dans l’état de Benue, Nigeria, a été déterminé par des tests anonymes aléatoire des volontaires fréquentant les consultations 
prénatales des divers hôpitaux à l’intérieur de la communauté. Trente de trois cent dix échantillons de sang ont été positifs 
de l’infection de VHB. 11,9% étaient au 3ème trimestre de leur grossesse et 58,1% étaient dans la tranche d’âge de 21 – 30 
ans. Les femmes analphabètes constituaient 14,4% de celles échantillons alors que 6,7% étaient fonctionnaires. Le statut de 
porteur de VHB a été déterminé par la présence de l’antigène de surface de l’hépatite B (HBsAg). Echantillons 
réactifsrépétés ont été confirmés  par enzymes liée Kit de dosageimmun/kit de dosage enzymatique d’immunosorbent lie 
(ELISA) (Diagnostic Automation, Inc., USA). La maternelle VHB statut d’infectiosé a été déterminée en analysant tous les 
échantillons HBsAg positifs pour présence de l’antigène de l’hépatite B (HBsAg). Une totales de trente (9,7%) femmes 
enceintes ont été identifiées comme porteuses de VHB et onze de ces trente ont été testées positives pour HBsAg. Donc, 
3,6%(11/310) de l’ensemble de la population d’étude est trouvé d’avoir une réplication virale élevée ainsi qu’une risque 




de façon significative avec l’utilisation antérieure de contraceptifs et l’étatanémique des sujets (P<0,05). Cette 
étudedémontre l’endémicité de l’infection par le VHB à Logo et le taux d’infectioséélevée, suggèrent que le VHB est 
probablement d’êtrecontracte par les deux moyens verticaux et horizon taux de transmission. Test pour HBsAg est 
recommandé pour toutes femmes enceintes à la première visite prénatale pour que les mères séropositives reçoivent une 
intervention rapide. 
Mots – clés : L’antigène de l’hépatite B, l’antigène de surface de l’hépatite B, séropositivité, femmes enceintes, nouveau – 
nés. 
INTRODUCTION 
Hepatitis B virus is a blood borne and sexually 
transmitted pathogen that is spread through 
percutaneous and mucosal exposure to infected 
blood and body fluids. The virus was first 
discovered as “Australia antigen” later named 
Hepatitis B surface antigen (HBsAg), in patient 
blood. Hepatitis B e antigen (HBeAg) was identified 
several years later as a marker for patients at high 
risk for transmission of the disease (1). The virus 
has caused several epidemics in parts of Africa and 
Asia (2) and approximately 350 million persons 
worldwide are infected with the virus (3, 4, 5, 6), 
resulting in 2 million deaths annually.  
When a pregnant woman is infected with HBV 
there is a chance she may infect her foetus. It has 
been reported that 10-20% of women seropositive 
for HBsAg transmit the virus to their neonates, but 
in women who are seropositive for both HBsAg and 
HBeAg; vertical transmission is approximately 90% 
(7, 8). 
Nigeria is classified among the countries highly 
endemic for viral hepatitis. Currently about 18 
million Nigerians are infected (9, 10). Many of these 
people may not be aware of the infection and hence 
fail to seek appropriate medical attention therefore 
progressing to chronic liver disease, cirrhosis and 
hepatocellular carcinoma, liver failure and death. 
Similarly when pregnant women are involved they 
constitute a serious health risk not only to their 
unborn child but the society at large. 
Although, studies have been carried out on HBV in 
other parts of the country, information is scarce on 
the prevalence of HBV among pregnant women in 
the rural parts of Benue state, in particular Logo 
LGA. The aim of this study therefore is to 
determine the prevalence of hepatitis B virus carrier 
and infectivity status of pregnant women attending 
ante natal clinics in Logo LGA of Benue state, 
Nigeria.   
MATREIALS AND METHODS 
AREA OF STUDY 
This study/research was conducted in the various 
health centres within the locality of Logo Local 
Government of Benue State which is located in an 
area covering about 1,408 Km 2  and  a population of 
169,063 in the 2006 census, in North-Central 
Nigeria. Its average annual Rainfall is 1200mm and 
the average annual maximum temperature is 
33.3OC. Logo is located on latitude 9o37’N and 
longitude 6o33’E and it is bordered in the East by 
Katsina Ala Local Government, in the North by 
Ukum Local Government, in the West by Taraba 
State and in the South by Buruku Local 
Government. Agriculture is the mainstay of its 
economy with the production of varieties of cash 
crops throughout the year.  
STUDY DESIGN 
The study was a hospital based descriptive cross 
sectional survey conducted between 1st   July, 2012 
and 30th April, 2013 at the antenatal clinics within 
Logo LGA, Benue State Nigeria. On every antenatal 
day, the pregnant women were given health talk on 
HIV/AIDS and hepatitis infections and were 
advised on the need to know their status. Only 
consenting attendees were recruited and included 
in the study. 
SUBJECTS  
Three hundred and ten pregnant women attending 
antenatal clinics in different hospitals in Logo Local 
Government were randomly selected from the clinic 
centres. Their specimens were retrieved and 
reviewed for analysis after informed consent. 
Information obtained from the case note included 
demographic characteristics, risk factors, blood 
group, haematocrit, and results of serological 
markers for hepatitis B virus. 
 Pre-structured questionnaires were administered to 
three hundred and ten consenting pregnant 
women. Each questionnaire was designed to obtain 
demographic data such as age, occupation and 
educational status. Risk factors information were 
also obtained which include the stages of 
pregnancy, history of blood transfusion, and history 
of STIs, whether or not respondents share sharp 





Ethical approval was gotten at the Benue state 
Ministry of Health and Human Services, Makurdi 
through the Medical Director of the General 
Hospital Ugba and the Logo Local Government 
Health Department.Informed consent was obtained 
from the from the antenatal clinic attendees with 
assurance that all information obtained would be 
treated as confidential and would be used for the 
purpose of this study only.    
SAMPLE SIZE AND ITS DETERMINATION  
Using the Kish (11) formula: n= (z2pq/d2 ) for 
determining adequate sample size and further 
correcting for population less than 10,000 using nf = 
n/1+(n/N) (12), 310 respondents were enrolled for 
this survey. 
COLLECTION OF BLOOD SAMPLES / SERUM 
PREPARATION  
Hepatitis B surface antigen (HBsAg) detection was 
done using the in vitro diagnostic kit manufactured 
by Cal – Tech Diagnostic, Inc. USA. The test kit 
(dipsticks) is a rapid immunochromatographic 
assay designed for qualitative determination of 
HBsAg in human serum or plasma. Assays were 
carried out at room temperature. The sera samples 
were removed from the freezer and left at room 
temperature to thaw. The test strips were removed 
from their foil pouches and immersed into serum 
samples with arrows pointing towards the samples. 
The strips were taken out after about 10secs and 
placed on a clean, dry, non-absorbent surface. This 
is to allow time for the reaction to take place. It was 
observed that the specimen was absorbed into the 
test strips and moved by capillary action upward 
towards the control line. Results were read after 
10mins post immersion. Positive samples generated 
a colour band in the test region of the strips and 
another in the control region while negative 
samples had a colour band in the control regions 
only.It utilizes a combination of monoclonal and 
polyclonal antigen body to selectively detect 
elevated level of HBsAg in serum/plasma. The test 
was carried out and interpreted according to the 
manufacturer’s instructions and in the laboratories 
of the hospitals were the samples were collected.
  
Reactive samples were stored in a freezer and 
further confirmed for HBsAg in the Innovative 
Biotechnology Laboratory Keffi where HBsAg 
positive samples were tested for HBeAg, associated 
with infectivity and active virus replication; using 
commercially available enzyme linked 
immounosorbent assay kit ELISA (Diagnostic 
Automation Inc. USA)  
DATA ANALYSIS 
Data from the questionnaires were analyzed using 
SPSS version 15.0. Chi-square was used to compare 
significant differences between HBV prevalence 
and risk factors. Significance was determined at P < 
0.05 at      95% Confidence interval. 
 RESULTS  
The results of the Seroprevalence study are 
presented in table 1, showed that of the three 
hundred and ten (310) pregnant women tested, 30 
(9.7%) pregnant women were seropositive for 
Hepatitis B surface antigen (HBsAg). Eleven (11) 
out of the thirty (30) pregnant women were 
identified as HBeAg positive. Hence, 3.6 % (11/310) 
of the entire study population was positive for 
HBeAg. 
With respect to age, the results showed that there is 
an increase in HBsAg titres with increase in age up 
to 30 years followed by a decline. Statistically, 
however, there was no significant association ( x2 
=1.960; p = 0.5808) between age and seroprevalence 
of HBV infection. 
The level of educational attainment and occupation 
and seroprevalence of the pregnant women are 
presented in table 2.It showed that there is an 
inverse relationship between educational 
attainment of the women and seroprevalence of 
HBV infection. Details show that women with high 
prevalence of the infection are illiterates (14.4%) 
while those with some levels of education had 
lower prevalence even though there was no 
significant association (x2 = 4.213  p = 0.239). 
Similarly, the results revealed that house wives had 
higher prevalence (13%) than the other women 
considered in this study. Despite this observation, 
no significant association (x2 =5.86    p = 0.119) 
between HBV infection and the occupation of the 
women. There was no significant association 
between infection and pregnancy stages of the 





TABLE 1: AGE SEROPREVALENCE OF HEPATITIS B SURFACE ANTIGEN AND HEPATITIS B E ANTIGEN AMONG 
THE PREGNANT WOMEN. 
Age group No. examined HBsAg seropositivity                    
(%) 















1             (10) 
7             (7.8) 
11           (11)  
9             (11.3) 
2             (8) 
0             (0)   
0             (0) 
1    (20) 
4    (4.4) 
4    (4) 
1     (1.3)  
1     (4) 
0     (0) 
0     (0) 
Total 310 30 (9.7%) 11(3.5%) 
X2=1.960, p = 0.5808                      X2 = 2.222,  p = 0.5276.     
 
TABLE 2: SOCIAL CHARACTERISTICS AND HEPATITIS B 





























15        (14.4) 
5          (5.1) 
6          (9.2) 
4          (9.5) 
 
1          (6.7) 
26        (13.0) 
1          (5.9) 
2          (2.6) 
Education; x2 = 4.213  p= 0.239; Occupation; x2 = 5.862  p = 0.119  
 
TABLE 3: HEPATITIS B VIRUS SEROPOSITIVITY 
AND STAGE OF PREGNANCY AMONG THE 
PREGNANT WOMEN. 
Trimester  No 
examined 












3    (7.7) 
 
5    (5.8) 
 
22   (11.9) 
   Total 310 30  (9.7) 
X2 = 2.239                  p = 0.326 
The frequency of HBV carriers did not vary 
significantly with blood transfusion, sharing 
needles, Alcoholic consumption, Herbal medicine 
use and history of STI(s). However, there was a 
significant frequency variation in the distribution of 
HBsAg and contraceptive use subjects (x2 = 7.212   p 
= 0.007) and anaemic and non- anaemic subjects (x2 
= 7.143 df = 1   p 0.008) (Table 4). HBV carriers also 
decrease as anaemia decreases significantly (x2 = 
15.048 df = 6    p = 0.0199), (Table 5). Among all the 
contraceptive devices used previously by the 
subjects, only users of oral pills were positive for 
HBeAg. (Table 6). 
DISCUSSION 
This study showed that the prevalence of hepatitis 
B virus (HBV) infection in apparently healthy 
pregnant women attending antenatal clinics in the 
major hospitals within Logo LGA, Benue State was 
9.7%, falls within figures reported for other African 
countries. This corroborates the World Health 




endemic area with prevalence greater than 8%. The 
HBsAg seropositivity of 9.7% among pregnant 
women in Logo shows that Logo like other areas in 
Nigeria is endemic for HBV infection. 
In related studies in different parts of Nigeria, 
higher prevalence rates of 13.8% were reported 
among pregnant women in Lagos (14) 11.6% in 
Maiduguri (15), 12.6% in North central Nigeria (10) 
11% in (16) and 12.3% in Minna (17). 
Other findings were, 8.3% in Zaria (18), 2.19% in 
Benin City (19), 4.3% in Port Harcourt in 2005 (20) 
and 2.89% in 2006 (21) and 5.7% in Ilorin (22).  The 
result of this study is higher than the 6.3% reported 
in pregnant women in Tanzania (23) and 3.7% in 
Ethiopia (24), showing that variations exist within 
the same continent of Africa. 
Similar studies in other parts of the world were 10% 
in India (25), 12% in Taiwan (26) and 17.3% in 
Burkina Faso (27) agreeing with Juszozyk (28) that 
the global prevalence of chronic HBV infection 
varies, highest in Africa, Asia and the western 
Pacific (>8%) to lowest in western Europe, North 




TABLE 4: DISTRIBUTION OF HBSAG POSITIVE CASES ACCORDING TO RISK FACTORS AMONG PREGNANT 
WOMEN. 
Risk Factors  No. 
Examined 




Sharing needles  
 











History of STI(s) 
Yes              
No 
 
Yes               
No 
 
Yes               
No 
 
Yes               
No 
 






Yes               
No 
15                
295 
 
270                    
40 
 
109              
201 
 
105               
205 
 
200                  
110 
 
45       
 265 
 
50                   
260 
3(20)                       
27 (9.2) 
 




12 (6)                                                       
 
11(10.5)                  
19 (9.3) 
 
 22(11)                                   
8(7.3) 
 




25 (9.6)      
1.453   0.228 
 
0.015   0.0903 
 
7.212    0.007 
 
0.095     0.758 
 
0.938    0.333 
 
 
7.143    0.008 
 
 






TABLE 5: AGE DISTRIBUTION OF HBSAG AND HBEAG AMONG ANAEMIC PREGNANT WOMEN 

























1     (10) 
4    (4.4) 
3     (3) 
2    (2.5) 
0      (0) 
0       (0) 








Total 310 45(5%) 10(3.2%) 5(1.6%) 
x2 = 15.048        p =0.0199               X2 =2.801     p =0.8334  x2 = 15.048        p =0.0199               X2 =2.801     p =0.833 
  
TABLE 6: DISTRIBUTION OF HBSAG AND HBEAG 
AMONG PREGNANT WOMEN THAT USED 
















14     (18.7) 
2       (7.7) 
0        (0) 
2      (28.6) 
5(6.7) 
0  (0) 
0  (0) 
0  (0) 
Total 109 18    (16.5) 5 (4.6) 
X2 = 4.128    p = 0.6594 
HBeAg seroprevalence of 3.6% in the entire study 
population implies that one out of every three HBV 
carriers (11/310) is at high risk of transmitting HBV to 
her neonate as well as higher chances of chronicity. 
This is alarming but tallies with the result of 
Olubuyide et al (29), who found 3.4% among HBsAg 
positive doctors and dentist at university teaching 
hospital Ibadan. However, it is very high when 
compared with 0.8% found by Madzine et al, (30), in 
Zimbabwe as well as 6.64% and 1.39% obtained by  
 
Harry et al (15) among blood donors and pregnant 
women in Maiduguri respectively. Hence the issue of 
vertical transmission in sub-Saharan Africa cannot be 
ignored. 
High prevalence of HBV carriers among teenagers 
(11-25) and 26-30 age groups and the corresponding 
high HBeAg prevalence among the same age group 
further show the severity of the infection in the 
community. 
Analyses showed that out of the 310 respondents 
(33.5%) were illiterates out of which 50% tested 
positive for HBsAg. There is an inverse association 
between educational status and HBsAg positivity 
with less educated women showing the highest 
positivity, indicating the positive influence of 
education and public enlightenment/ awareness on 
the carrier rate of HBV infection. Although HBV 
infection is considered one of the most important 
occupational infectious hazards in developed 
countries (31), result from this study did not reveal 
statistical significance between HBV seropositivity 
and the different occupations of the pregnant women 
studied. 
Most of the studied women (185, 59.7%) were in the 
3rd trimester of gestation. This group also had the 




followed by those in the 2nd trimester of gestation, 
results revealed no significant association between 
infection and pregnancy stages of the women. 
The distribution of HBsAg and HBeAg among 
teenagers and 26-30 years age groups as shown in 
table 4 and 5 could be due to anaemia which 
significantly decreases with increasing age. It could 
also be attributed to the effect of oral pills table (6) 
towards higher expression of HBeAg (Table 1) among 
the teenagers and 26-30 age groups. Oral pills are 
steroid hormone prepared in tablet form and have 
slower but longer action in the body stimulating the 
immune system for a longer period of time. They 
have been reported to immunosuppress (blind) 
lymphocytes by reducing the reactivity of T-
lymphocytes and reduce immunoglobulin secretion 
(32; 33). Hence anaemia, effect of oral pills and other 
unanalyzed factors such as HIV and malaria may 
have contributed immensely to the endemicity of 
HBV infection among pregnant women in the study 
community, Logo LGA. 
CONCLUSION 
Since the virus can be transmitted from infected 
mother to the offspring especially at birth, the 
presence of HBV infection in women in general and 
pregnant women in particular calls for concern. Free 
screening of all pregnant women should be 
incorporated in the antenatal and post-natal infection 
programmes in hospitals to prevent potential 
infection of the infants by their infected mothers. The 
use of other HBV infection serological markers such 
as anti HBs, anti HBc, and HBe as well as HIV co- 
infection  and cases of HBsAg positive women and 
the effects of the  positivity on their babies is 
advocated for further studies. 
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